A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

By Jack Janetzki, Lecturer in Pharmacy and Pharmacology, Adelaide University
Lisa Kalisch Ellett, Research Fellow, Quality Use of Medicines and Pharmacy Research Centre, Adelaide University

A new medicine for attention-deficit hyperactivity disorder (ADHD) has just entered the treatment toolbox: centanafadine, a once-a-day tablet sold under the brand name Simtriyo.

It has been approved in the United States for adults and children aged six years and older but isn’t yet available in Australia.

So how does it work? How is it different to other ADHD medications? And what are the potential side effects?

~	Russia: Cluster Munition Attack on Kyiv a Potential War Crime

~	US: Federal Agencies Abandon Civil Rights Duties

~	Afghanistan: Taliban Forcibly Disappear 6 Rights Workers

~	Netanyahu rejects Trump’s Gaza roadmap – history tells us Israel may be planning to stay

~	As oil profits skyrocket, calls for windfall taxes rise

~	Layoffs tied to AI hurt worker productivity – and the reason may surprise managers

~	What it’s like to discover an ancient Egyptian tomb – and the race against time to preserve it

~	Is hope back? Why it’s such an important part of Andy Burnham’s big plan

~	Putting out wildfires: how peat restoration has reduced fire risk in Indonesia’s tropical forests

~	How Gen Z and India’s Cockroach Janata Party are successfully challenging Narendra Modi

A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

It belongs to a new class of ADHD…Read complete article© The Conversation - Wednesday, August 12, 2026

It belongs to a new class of ADHD…

Read complete article
© The Conversation - Wednesday, August 12, 2026